Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 17/20 | 0.59 |
| ▸ | CA2 | P00918 | 17/20 | 0.59 |
| ▸ | CA9 | Q16790 | 16/20 | 0.59 |
| ▸ | CA12 | O43570 | 8/20 | 0.59 |
| ▸ | CA4 | P22748 | 5/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.59 |
| ▸ | CA7 | P43166 | 4/20 | 0.59 |
| ▸ | CA3 | P07451 | 3/20 | 0.59 |
| ▸ | CA6 | P23280 | 3/20 | 0.59 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.59 |
| ▸ | CA5A | P35218 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13718831 | 0.88 | TAAR1 (0.45) | CA1CA2CA9CA12CA4 | |
| SCHEMBL13718482 | 0.84 | HTR7 (0.41) | CA1CA2CA9CA12CA4 | |
| SCHEMBL13717751 | 0.83 | NPC1 (0.44) | — | |
| SCHEMBL13718623 | 0.82 | ADORA2A (0.46) | CA1CA2CA9CA12CA4 | |
| SCHEMBL13718775 | 0.82 | LMNA (0.45) | — | |
| SCHEMBL13717813 | 0.82 | KDM4E (0.40) | CA1CA2CA9CA12CA4 | |
| SCHEMBL13717978 | 0.79 | CA1 (0.51) | CA1CA2CA9CA12CA4 | |
| SCHEMBL13718017 | 0.79 | ALDH1A1 (0.48) | MEN1KMT2A | |
| SCHEMBL1021374 | 0.79 | ALDH1A1 (0.37) | — | |
| SCHEMBL13718539 | 0.79 | BCHE (0.38) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160289211-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289211-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289211-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2016-10-06 | — | — | US | disclosed |
| US-9278962-B2 | Certain heterocycles, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278962-B2 | Certain heterocycles, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278962-B2 | Certain heterocycles, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20140330011-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140330011-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140330011-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8759380-B2 | Certain heterocycles, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759380-B2 | Certain heterocycles, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759380-B2 | Certain heterocycles, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130060025-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | ASHCRAFT LUKE W (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130060025-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | ASHCRAFT LUKE W (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130060025-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | ASHCRAFT LUKE W (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120289698-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120289698-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120289698-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140330011-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ZYX | CA1 2315/4885CA2 1805/4885CA9 1977/4885 |
| US-20120289698-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ZYX | CA1 2315/4885CA2 1805/4885CA9 1977/4885 |
| US-20160289211-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1S | CA1 2290/4885CA2 2328/4885CA9 2622/4885 |
| US-20130060025-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ZYX | CA1 2315/4885CA2 1805/4885CA9 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.